CPH •
Healthcare •
Biotechnology •
Quote as of 07/24/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeCPH
Market Capitalization50,610 mln
Float132 mln
Earnings Date08/20/2026
EPS
5.80
Stretched
P / E
39.03
Overvalued
1-Year Forecast
299
Strong upside
Relative Strength
3
/ 100
Severely lagging
Debt / Equity
0.06
Debt-free
ROE
20.91
Strong
Business Description
Founded in 1923 and based in Hørsholm, Denmark, ALK-Abelló is a medical company focused on helping people manage and treat allergies. Its core products include a range of immunotherapy treatments ? delivered as tablets, drops, or injections ? that target common allergies such as grass and tree pollen, house dust mites, ragweed, and peanuts, along with emergency medicines for severe allergic reactions like anaphylaxis. The company also offers diagnostic tools, a digital platform to help patients track and manage their condition, and is developing new biological treatments for food allergies. ALK-Abelló operates across Europe, North America, Asia, and other markets, working with partners such as Torii Pharmaceutical and Dr. Reddy's Laboratories to bring its products to patients worldwide.